Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9429035 | 0.81 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL5637462 | 0.65 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL28445790 | 0.64 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL31511814 | 0.64 | GPR84 (0.31) | TRPA1 | |
| SCHEMBL11569287 | 0.63 | — | — | |
| SCHEMBL168345 | 0.63 | TRPA1 (0.56) | TRPA1 | |
| SCHEMBL6272460 | 0.62 | ALDH1A1 (0.32) | — | |
| SCHEMBL20145049 | 0.61 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL6838816 | 0.60 | — | — | |
| SCHEMBL2141215 | 0.59 | TRPA1 (0.33) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | CARLSSON JENS (SE) | 2024-06-27 | — | — | US | disclosed |
| EP-4329883-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | Carlsson, Jens (SE) | 2024-03-06 | — | — | EP | disclosed |
| EP-3762394-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | Medivir Aktiebolag (SE) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AB (SE) | 2020-12-24 | — | — | US | disclosed |
| WO-2019172835-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AKTIEBOLAG (SE) | 2019-09-12 | — | — | WO | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| WO-2018226150-A1 | PYRAZOLOPYRIMIDINE AS MALT-1 INHIBITORS | MEDIVIR AKTIEBOLAG (SE) | 2018-12-13 | — | — | WO | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| CN-101273042-B | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARM LTD | 2013-11-06 | — | — | CN | disclosed |
| WO-2007014919-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014920-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014927-A2 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006707-A1 | 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1713822-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006084688-A1 | HIV protease inhibitors | MEDIVIR AB (SE) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005073216-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | TRPA1 3647/4885 |
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | FURIN, ACE, PEPD | TRPA1 1819/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | TRPA1 3647/4885 |
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | PNP, NUDT1, TYMP | TRPA1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.